Australia’s COVID-19 booster vaccination program is set to be extended to include 16 and 17-year-olds after the Therapeutic Goods Administration (TGA) gave the green-light for Pfizer's Comirnaty to be used as a top-up shot in that age group.
Details as to when the rollout of booster doses in this cohort will commence are expected to be announced by the Australian Technical Advisory Group on Immunisation (ATAGI) in the coming days.
The TGA’s decision to grant provisional approval for the booster for individuals aged 16 to 17 years follows similar steps by regulators in the US, UK and Israel.
| | | | | BREAKING NEWS | | Fri 28 Jan 2022 |
|
| | | | COVAX booster program extended | Australia’s COVID-19 booster vaccination program is set to be extended to include 16 and 17-year-olds after the Therapeutic Goods Administration (TGA) gave the green-light for Pfizer's Comirnaty to be used as a top-up shot in that age group.
Details as to when the rollout of booster doses in this cohort will commence are expected to be announced by the Australian Technical Advisory Group on Immunisation (ATAGI) in the coming days.
The TGA’s decision to grant provisional approval for the booster for individuals aged 16 to 17 years follows similar steps by regulators in the US, UK and Israel.
| | More details in today's issue of Pharmacy Daily.
|
| | | | | | | For more news visit: | | pharmacydaily.com.au | Pharmacy Daily - a division of Business Publishing Group
PO Box 1010 Epping NSW Australia 1710
Level 2, Suite 1 64 Talavera Rd Macquarie Park NSW 2113 | | |
| To ensure you continue to receive email from Pharmacy Daily reliably please add info@pharmacydaily.com.au to your 'Safe Senders' list and set images to always display.
To forward this email to a friend click here
To receive your own copy of Pharmacy Daily sign up here.
To modify subscription details click here
To unsubscribe click here.
The Therapeutic Goods Advertising Code (No.2) 2018 requires strict compliance. View the code at https://www.legislation.gov.au/Series/F2018L01524. |
|
| |
| |
| |
|
